VIR Vir Biotechnology, Inc.
Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Vir Biotechnology, Inc. (VIR) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: FDA revoked EUA for sotrovimab COVID-19 treatment December 2024, eliminating expected future US revenue from this product
- • Material update: Net loss $395.1M for nine months ended Sept 30, 2025 vs prior $417.4M period; accumulated deficit $1.2B reflects ongoing R&D investment
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.